Latorre, Jessica and Ortega, Francisco J. and Linares-Pose, Laura and Moreno-Navarrete, Jose M. and Lluch, Aina and Comas, Ferran and Oliveras-Canellas, Nuria and Ricart, Wifredo and Hoering, Marcus and Zhou, You and Liebisch, Gerhard and Haridas, P. A. Nidhina and Olkkonen, Vesa M. and Lopez, Miguel and Fernandez-Real, Jose M. (2020) Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes. EBIOMEDICINE, 53: 102697. ISSN 2352-3964,
Full text not available from this repository. (Request a copy)Abstract
Background: While the impact of metformin in hepatocytes leads to fatty acid (FA) oxidation and decreased lipogenesis, hepatic microRNAs (miRNAs) have been associated with fat overload and impaired metabolism, contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Methods: We investigated the expression of hundreds of miRNAs in primary hepatocytes challenged by compounds modulating steatosis, palmitic acid and compound C (as inducers), and metformin (as an inhibitor). Then, additional hepatocyte and rodent models were evaluated, together with transient mimic miRNAs transfection, lipid droplet staining, thin-layer chromatography, quantitative lipidomes, and mitochondrial activity, while human samples outlined the translational significance of this work. Findings: Our results show that treatments triggering fat accumulation and AMPK disruption may compromise the biosynthesis of hepatic miRNAs, while the knockdown of the miRNA-processing enzyme DICER in human hepatocytes exhibited increased lipid deposition. In this context, the ectopic recovery of miR-30b and miR-30c led to significant changes in genes related to FA metabolism, consistent reduction of ceramides, higher mitochondrial activity, and enabled b-oxidation, redirecting FA metabolism fromenergy storage to expenditure. Interpretation: Current findings unravel the biosynthesis of hepatic miR-30b and miR-30c in tackling inadequate FA accumulation, offering a potential avenue for the treatment of NAFLD. Funding: Instituto de Salud Carlos III (ISCIII), Govern de la Generalitat (PERIS2016), Associacio Catalana de Diabetis (ACD), Sociedad Espanola de Diabetes (SED), Fondo Europeo de Desarrollo Regional (FEDER), Xunta de Galicia, Ministerio de Economia y Competitividad (MINECO), "La Caixa" Foundation, and CIBER de la Fisiopatologia de la Obesidad y Nutricion (CIBEROBN). (c) 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | HIGH-THROUGHPUT QUANTIFICATION; FATTY LIVER-DISEASE; DE-NOVO LIPOGENESIS; MOLECULAR-MECHANISMS; METFORMIN; METABOLISM; NAFLD; ATHEROSCLEROSIS; TRANSCRIPTION; CHOLESTEROL; MicroRNAs; AMPK; Hepatocytes; Fatty acid homeostasis; Steatosis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Mar 2021 10:40 |
| Last Modified: | 29 Mar 2021 10:40 |
| URI: | https://pred.uni-regensburg.de/id/eprint/45007 |
Actions (login required)
 |
View Item |
